Diabetes therapy - Akesis Pharmaceuticals

Drug Profile

Diabetes therapy - Akesis Pharmaceuticals

Alternative Names: AKP-320

Latest Information Update: 20 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akesis Pharmaceuticals
  • Class Chromium compounds; Vanadium compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Feb 2009 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in USA (PO)
  • 15 May 2006 Akesis and Profil Institute for Clinical Research have signed a consulting agreement for clinical trials in type 2 diabetes
  • 14 Feb 2005 Clinical trials in Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top